The Albanese Government is continuing to deliver cheaper medicines with Australians living with debilitating conditions including cancers and rare diseases having access to treatments on the Pharmaceutical Benefits Scheme (PBS) from today.
Elranatamab (Elrexfio®) will be listed for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy.
RRMM is a type of blood cancer in which the disease either returns after a period of improvement or does not respond to initial treatment.
Each year, more than 2,500 new cases are diagnosed with the disease predominantly affecting older adults, with most diagnoses occurring in people over the age of 65.
Without subsidy patients might pay $5,000 per script.
Fedratinib (Inrebic®) will be listed for the first time for the treatment of patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis.
Myelofibrosis is a rare type of blood cancer that interrupts the body's normal production of blood cells. With people with myelofibrosis, abnormal blood forming cells grow uncontrollably.
Inrebic® is a selective inhibitor that works by blocking the overactive signals that causes abnormal blood cells to grow.
In 2025, over 2,000 patients accessed a comparable treatment through the PBS. Without subsidy patients might pay $6,000 per script.
Garadacimab (Andembry®) will be listed for the first time for the prevention of Hereditary angioedema (HAE) in patients aged 12 and over.
HAE is a rare genetic disorder caused by a deficiency or dysfunction of C1esterase inhibitor (C1INH). Given the C1INH helps regulate inflammation and swelling, people with HAE experience recurrent, unpredictable episodes of severe swelling.
Andembry® is a prophylactic therapy designed to prevent angiodedema attacks before they occur.
In 2025, around 180 patients accessed a comparable treatment through the PBS. Without PBS subsidy patients might pay over $30,000 per script.
Givosiran (Givlaari®) will be listed for the first time for the continuing treatment of Acute Hepatic Porphyria (AHP) in adults and adolescents aged 12 years and older.
AHPs are rare genetic diseases that affect the liver and nervous system by causing a buildup of harmful substances in the body, leading to sudden attacks such as severe abdominal pain and muscle weakness.
Givlaari® is intended for use as a long-term therapy and works by reducing the build-up of toxic substances that triggers these attacks.
Around 500 Australians are expected to benefit from this listing each year. Without the PBS subsidy, patients could pay $154,000 per script.
Mogamulizumab (Poteligeo®) will be listed for the first time for the treatment of patients with relapsed or refractory Cutaneous T-cell lymphoma (RR-CTCL).
CTCL is a rare type of non-Hodgkin lymphoma that affects the skin and in more advanced cases involves the lymph nodes, blood and internal organs.
Relapsed or refractory (RR) CTCL occurs when the lymphoma reappears or grows again or the lymphoma does not respond to treatment.
Poteligeo® helps the immune system find and destroy malignant cells which reduces disease burden and potentially improve symptoms.
In 2025, more than 100 patients accessed a comparable treatment through the PBS. Without subsidy patients might pay $9,000 per script.
Zilucoplan (Zilbrysq®) will be listed for the first time for the treatment of generalised myasthenia gravis.
Myasthenia gravis is a chronic autoimmune disorder where the body generates antibodies that interfere with muscle and nerve communication, leading to skeletal muscle weakness.
Zilbrysq® works by protecting the connection between nerves and muscles from immune system damage.
An estimated 2,600 Australians were living with myasthenia gravis in 2009. Without subsidy patients might pay $33,000 per script.
PBS listings mean eligible patients will pay a maximum of $25 per script, or just $7.70 with a concession card.
Since July 2022, the Albanese Government has approved extra funding for 431 new and amended listings on the PBS.
Quotes attributable to Minister Butler:
"The Albanese Government is working to ensure Australians living with cancer and rare diseases have access to life changing medicines.
"These new PBS listings will significantly reduce costs for patients, making the treatments accessible for thousands of Australians.
"We want all Australians to get the treatment they need faster and live better lives for longer."
